31 results about "Wedelolactone" patented technology

The invention provides a compound nano graphene oxide drug carrier, which is the drug carrier is used for combining a natural anti-neoplastic extract wedelolactone and a photosensitizer indocyanine green to the surface of the nano graphene oxide through Phi-Phi stacking interaction. A preparation method of the compound nano graphene oxide drug carrier comprises the following steps: graphene oxideis processed through an ultrasonic method, the nano graphene oxide is obtained, the Phi-Phi stacking interaction is used, and wedelolactone and indocyanine green are loaded on the surface of the nanographene oxide in order. The preparation method is simple, the particle size of the nano graphene oxide is controlled at 100-200 nm, cycle time of the drug carrier in body can be prolonged, the compound nano graphene oxide drug carrier can absorb 600-900 nm near infrared, luminous energy is transformed to heat energy, photo-thermal treatment is realized, under irradiation of 808 nm near infrared,active oxygen is generated, and a purpose of photodynamic therapy is realized.

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.

The invention relates to a molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and a preparation method thereof. The molecular traditional Chinese medicine sustained-release tablet comprises molecular traditional Chinese medicine ingredients and pharmaceutically allowed auxiliary material ingredients, wherein the molecular traditional Chinese medicine components comprise 1-5 parts of specnuezhenide (ligustrum lucidum), 1-5 parts of wedelolactone (eclipta prostrata), 0.5-3 parts of paeoniflorin (peony), 0.5-3 parts of psoralen (psoralea corylifolia), and 1-5 parts of diosgenin (yam) ]; and the auxiliary material ingredients comprise 10-50 parts of sodium alginate, 1-5 parts of carbomer (934) , 10-30 parts of hydroxypropyl methyl cellulose, 10-40 parts of lactose, and 1-5 parts of magnesium stearate. Based on a theory of Chinese medicine and a theory of sustained-release preparations, Chinese medicine pathological features of postmenopausal osteoporosis, and scientific compatibility, the molecular traditional Chinese medicine sustained-release tablet which is safe and reliable, high in bioavailability and significant in curative effect is developed.